Drug Trial Radar · NCT06940154
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Aug 12, 2025
Primary completion
Jul 30, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- Connect Biopharm LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Conditions
- COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringeCombination product
Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
Matching placebo in prefilled syringeDrug
Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment failure rateTime frame: 28 days
Locations
52 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Lung Health Center
Birmingham, Alabama
Leland Stanford Junior University, Stanford Hospital
Palo Alto, California
Amicis Research Center
Valencia, California
National Jewish Health
Denver, Colorado
Columbus Clinical Services, LLC
Miami, Florida
Pharmax Research of South Florida, Inc.
Miami, Florida
Health Synergy Clinical Research, LLC
West Palm Beach, Florida
Primeway Clinical Research Group
Fayetteville, Georgia
Pivotal Research Solutions
Stonecrest, Georgia
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Ochsner Medical Complex - The Grove
Baton Rouge, Louisiana
Stony Brook University Hospital
Stony Brook, New York
Duke Asthma, Allergy, and Airway Center
Durham, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Clinical Research of Rock Hill
Rock Hill, South Carolina
Inquest Clinical Research
Baytown, Texas
Premier Pulmonary Critical Care and Sleep Medicine
Denison, Texas
DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials
McAllen, Texas
Vermont Lung Center
Colchester, Vermont
Carilion Medical Center / Carilion Roanoke Memorial Hospital
Roanoke, Virginia
Centro de Diagnostivo y Rehabilitación S.A. - CEDIR
Santa Fe, Argentina
Hospital Italiano de Buenos Aires
CABA, Buenos Aires, Argentina
CEMER - Centro Medico de Enfermedades Respiratorias
Florida, Buenos Aires, Argentina
Instituto Ave Pulmo-Fundacion Enfisema
Mar del Plata, Buenos Aires, Argentina
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Centro Medico Ipam S.A
Rosario, Santa Fe Province, Argentina
Investigaciones en Patologias Respiratorias SRL
San Miguel de Tucumán, Tucumán Province, Argentina
The Canberra Hospital
Garran, Australian Capital Territory, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
St. Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Bendigo Health
Bendigo, Victoria, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
JSC "National Center for Lung Health"
Tbilisi, Georgia
LLC "Israel-Georgian Medical Research Clinic Healthycore"
Tbilisi, Georgia
Acad. Chapidze Emergency Cardiology Center LLC
Tbilisi, Georgia
Acad. G. Chapidze Emergency Cardiology Center
Tbilisi, Georgia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.